Neoadjuvant Capecitabine, Oxaliplatin, Docetaxel and Atezolizumab in Resectable Gastric and GE-junction Cancer (PANDA)

NCT03448835 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Stomach Cancer
Gastro Esophageal Junction Cancer

Interventions

DRUG: Atezolizumab
DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Docetaxel

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]